Between 2001 to 2011, annual age-adjusted incidence increased from 0.55/100,000 to 0.78/100,000, demonstrating an increasing trend with age. Incidence peaks in individuals over 70 years of age ...
The phase 1 trial is testing the safety tolerability, pharmacokinetics, and pharmacodynamics of PVT201 in healthy volunteers and patients.
The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.
Patients with ATTR-PN have a high rate of comorbidities and substantial direct healthcare and economic burdens, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback